header logo image


Page 712«..1020..711712713714..720730..»

Stem Cell Assay Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 – Vital News 24

January 25th, 2020 1:42 am

Stem Cell Assay Market

New Jersey, United States, The report offers an all-inclusive and accurate research study on the Stem Cell Assay Market while chiefly that specialize in current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly have the benefit of the thorough marketing research provided within the report. The authors of the report have compiled an in depth study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to induce a decent understanding of future development of the Stem Cell Assay market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to assist with comprehensive evaluation of the Stem Cell Assay market.

Global Stem Cell Assay market was valued at USD 536.53million in 2016 and is projected to reach USD 2858.95millionby 2025, growing at a CAGR of 20.43% from 2017 to 2025.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=24266&utm_source=VN24&utm_medium=002

Top 10 Companies in the Global Stem Cell Assay Market Research Report:

Global Stem Cell Assay Market: Competitive Landscape

The research analysts who have authored this report are experts in performing competitive analysis of the global Stem Cell Assay market. They have deeply profiled leading as well as other players of the global Stem Cell Assay market with large emphasis on their market share, recent developments, business overview, markets served, and growth strategies. The report not only provides valuable insights into the competitive landscape but also concentrates on minor as well as major factors influencing the business of players. The product portfolios of all companies profiled in the report are compared in quite some detail in the product analysis section.

Global Stem Cell Assay Market: Segment Analysis

The global Stem Cell Assay market is segmented according to type, application, and region. The analysts have carefully studied each segment and sub-segment to provide a broad segmental analysis of the global Stem Cell Assay market. The segmentation study identifies leading segments and explains key factors supporting their growth in the global Stem Cell Assay market. In the regional analysis section, the report authors have shown how different regions and countries are growing in the global Stem Cell Assay market and have predicted their market sizes for the next few years. The segmental analysis will help companies to focus on high-growth areas of the global Stem Cell Assay market.

Global Stem Cell Assay Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=VN24&utm_medium=002

Table of Content

1 Introduction of Stem Cell Assay Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Assay Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Assay Market, By Deployment Model

5.1 Overview

6 Stem Cell Assay Market, By Solution

6.1 Overview

7 Stem Cell Assay Market, By Vertical

7.1 Overview

8 Stem Cell Assay Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Assay Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=VN24&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

See more here:
Stem Cell Assay Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 - Vital News 24

Read More...

Cell Separation Technology Market Statistics, Demand and Forecasts to 2027 Examined in New Research Report – Dagoretti News

January 25th, 2020 1:42 am

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request PDF Sample of Cell Separation Technology Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases.

Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Enquiry for Discount on Cell Separation Technology Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration(CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

Read this article:
Cell Separation Technology Market Statistics, Demand and Forecasts to 2027 Examined in New Research Report - Dagoretti News

Read More...

UFO Religion the Ralians Know They’re ‘Quite Out There’ – VICE UK

January 25th, 2020 1:42 am

"The only difference between us and anybody else is that we believe all life was created by the Elohim, who were extra-terrestrials visiting Earth from another planet," Glenn Carter, president of the British Ralian movement, explains to me. "The rest of our behaviour is the same as any other human being, or group."

The Ralian movement, known to many as a "UFO religion", started in France in the 1970s. Their prophet a French former journalist and pop star called Ral (born Claude Vorilhon) claims that the origins of all life on Earth were explained to him during an alien encounter in 1973. The message he was given by the visitors became the Ralian philosophy, which he released in books that include The Book Which Tells the Truth and Extraterrestrials Took Me to Their Planet.

The belief system is one that argues for personal and sexual freedom, love, science and technological advancement. Oh, and that humans were put here thousands of years ago by aliens (or "advanced humans from another planet", to be exact) as an experiment. Since then, Ral has led this "atheist religion" through social justice campaigns, televised debates and battles with bad press, amassing hundreds of thousands of devoted followers from Canada to Japan.

Glenn Carter. Photo by the author.

"We were created in the image of another humanity," Glenn tells me over a pint in Leigh-on-Sea, Essex, before comparing life on Earth to the Eden Project in Cornwall. "They monitor us and wish one day to return to share their scientific knowledge [...] I discovered the philosophy in a bookshop and contacted the organisation. Eventually, they asked me to run it here," he explains.

Outside of his beliefs, Glenn is an actor known for playing Jesus in the Broadway, West End and movie versions of Jesus Christ Superstar a career that took a hit when he accepted the presidency.

"It has affected my life incredibly through the bigotry of other people," says Glenn, now in his fifties. "I won't be employed by certain producers I was really on the rise as a West End actor in musical theatre; I was on Broadway, winning awards, appearing in films, and the whole thing completely stopped as soon as an actress I worked with said, 'He's the guy that believes in aliens and he runs the Ralian movement'"

The creators the Ralians believe in are known as the Elohim, which, according to the prophet Ral, means "those who came from the sky" in the original Hebrew it's translated from. In Christianity and Judaism, the word simply means "God", but there has been much debate and disagreement around the translation of the word. It does appear to be plural, which indicates it could possibly translate to "gods" as opposed to God.

This speculation about ancient astronauts isn't unique to Ralism. Books like Erich von Daniken's 1968 epic Chariots of the Gods? and The Spaceships of Ezekial, written by a NASA engineer named Josef F Blumrich in 1974, popularised theories that Earth was visited long ago by extraterrestrials, and that some of those visitations even appear in religious scriptures.

Unpacking and reinterpreting stories from the Old Testament concerns much early Ralian literature. According to Ral, the Bible and other holy books are full of alien encounters and messages, but they've been misinterpreted over time. With this in mind, they believe that the prophets from all other religions were actually preaching messages from the Elohim, too including Ral's alleged half-brothers Jesus, Mohammed and Buddha.

UK Ralians and the author (second from left) at a dinner celebrating the first encounter.

"I think the best thing about the Ralian movement is that it encourages people to be free. That's what drew me to it," says Jamie, an IT technician and recent convert, at one of their monthly meet-ups. He used to identify with Buddhist teachings, but his old Christian church said they were "bad spirituality". He tells me Ralians remind him of the Buddhists he's met, that "they are very kind and have inner peace The main criticism of Ralianism is its size. Because it's very small, it's seen as a cult. People are scared of it."

Jamie was introduced to Ralism by a veteran UK member named Sakina, while she was working as a stripper: "He came to me one night, and simply by the way I connected, and the tender way I made him feel welcome," she says, "he asked me, 'What do you feel about life?'"

The pair started talking meditation and ended up at Ralian philosophy, with Jamie eventually subscribing to the belief system.

Unlike Sakina, however, not all Ralians openly discuss their faith in the workplace take Karen, for instance, who found the movement in her late fifties: "I work for the Metropolitan Police Service, which is very diverse and encourages diversity, but I know that if I was to say where I was coming from, [some people] would find that quite difficult. And, to be honest, I don't think they need to know."

I ask what her family think about her beliefs. "When I first told my husband, he was absolutely fine with it he's an atheist himself," she says. "The only concern he had was that it might be a cult and would they be taking me away from him? Three years down the line, we're still together, nothing has changed."

What about her son? "He's 30 and finds it amusing. He doesn't believe in anything himself. When I told him about the Ralian movement he went online and saw all these things about sex orgies [laughs] For his mum to be involved with that kind of organisation was really funny to him. He takes it with a pinch of salt."

Sex and promiscuity have been associated with the sect for decades, salacious articles appearing in tabloid newspapers, "Ral's Girls" popping up in Playboy magazine. It's true that the philosophy promotes sexual freedom, but the members I speak to insist that sex is found in the movement no more than it is anywhere else.

"I guarantee that lots of people have had sex in the Ralian movement with people they've met in the Ralian movement," says Glenn. "But the same thing happens at Barclays bank, between teachers at high schools, or wherever. Nothing is organised by the Ralian movement. It would be a waste of time because we've got so many other things to discuss and do."

Sandra is a Swedish-born Ralian living in London. She works in the tourism business and was hosting the monthly meeting in her central London office space one Sunday morning. "It's been quite hard sometimes, in my relationship with my friends. They all felt it was so strange," she explains earnestly. "But the Ralian values have always been my values."

Sandra found the religion through her interest in musical theatre, a fan of Glenn's who decided to email him on a whim. Eight years later she is an active member, organising events and getting involved in Free Meditation campaigns around the UK.

It's difficult to find anything written about the community that doesn't dismissively brand it a "cult" old VICE coverage included. I ask Glenn how this feels. "It's offensive it's literally like using the N-word to describe a black person," he says, perhaps underestimating the weight of using "literally" in this comparison. "The word 'cult' means, in its original sense, 'system of religious worship'. So, Christianity is a cult because it's a system of religious worship. So is Judaism, Islam and every religion you can name! It's designed to colour people's opinions of you, but that's just their own stupid insecurities."

These thoughts are echoed by Tomi, a long-haired Ralian rocker who lives in Liverpool: "It's a way to discredit us, because the old religions and the establishment, they are afraid of this message. We are a true revolution in all aspects of life."

Tomi is the president of the Romanian Ralian branch and has appeared all over Romanian TV. When I first met him in London he embraced me passionately and said, "You are my brother," a metal Ralian symbol hanging from his neck. Shortly after, we stood in a circle with some other followers, closed our eyes and attempted to make contact with the Elohim. The "transmission" was somewhere between a guided meditation and a good old-fashioned prayer, and although we got no response from the Elohim, everybody was thankful afterwards.

Ralian pensioners in the garden in Norfolk. Photo: provided.

After early coverage of the movement and a multitude of TV interviews with their founder through the 1980s and 90s, the organisation could have slipped quietly out of the public eye. However, in 2002 they made international headlines when Dr Brigitte Boisselier a Ralian bishop with a PhD in Analytical Chemistry claimed the group had cloned a human baby. The movement are big advocates for cloning, setting up the organisation Clonaid in 1997, dedicated to their quest for immortality. "Ralians believe there is no afterlife at all," Glenn tells me. "The only afterlife is the one that science could create for you."

As the president of UK Ralians, Glenn appeared on TV a lot at that time to defend cloning from an ethical and philosophical standpoint. This claim, and the debates that followed, drew a lot of attention to the religion, and even inspired a piss-taking sketch on Saturday Night Live. "Cloning is happening all the time, every day," says Glenn, confidently. "The only difference between stem-cell therapies and reproductive human cloning is that, in stem-cell therapies, you end the life that is developing, you harvest the cells and you don't allow it to grow."

Dr Boisselier never provided proof that Clonaid had cloned baby "Eve", and at the time the whole saga was criticised as a hoax by both journalists and scientists. When asked, Glenn can't say for certain if it really happened either.

As well as Clonaid, Ralians also started an anti-FGM charity called Clitoraid, campaigned to rehabilitate the swastika (a symbol they use as their own, placed inside the star of David), staged topless protests for equality, supported gay Pride events worldwide and even tried to sue the Pope over child sexual abuse in the Vatican. Some of their tactics in the fight for social justice have, admittedly, not helped their reputation like the time they handed out 10,000 condoms to students in Montreal to protest the Catholic School Commission's decision to veto high school condom machines. However, this doesn't stop them from fighting the good fight. "Fuck the oppression that society puts on us," says Glenn.

When I ask about UFO encounters, some members come forward with their stories all fairly classic lights-in-the-sky anecdotes, but without the usual fear and bewilderment. "Each time, I had a huge sensation of warmth, and sometimes a little tear," Sakina tells me, wistfully. "To witness it was such a beautiful thing."

The Ralian idea that we're being watched from above isn't just one for religious circles; even scientists and astronomers have entertained the idea known as the "zoo hypothesis".

On my last visit to the group, we gather on the 13th of December at a restaurant in Londons Docklands, called Area 51 Tex Mex to celebrate the anniversary of the prophet's first alien encounter. We watch a video from one of their Happiness Academy events essentially a big Ralian get-together and, although the nudity in it probably doesn't help their "sex cult" reputation, I can't deny it looks way more fun than any Sunday service I've attended.

As well as being a "religion-for-atheists" where freedom reigns supreme, Ralism's lasting pull is also identified as its championing of science.

"I've always been into the science part of it," Sandra tells me. "Finding spirituality together with science really spoke to me." She then goes onto casually tell me that "evolution was disproved in 1993", citing Dr Michael Behe and his theory of Irreducible Complexity a theory positing that humanity is the result of intelligent design, and one that has been rejected by the majority of the scientific community.

As the meeting draws to a close, I ask how it feels to regularly watch their white-clad prophet, Ral, face laughter and ridicule from journalists and TV audiences. "For me, it is hard. We have all experienced that in some way," says Sandra. "We are quite 'out-there', and that makes people insecure. I just try to have compassion for the people that think in that way."

Ralism is not without its unanswered questions and ambiguities and its past isn't entirely unblemished, but which religion is? Where other spiritual groups have grown and (sometimes literally) died out, imploded or been abandoned, this philosophy is seemingly more robust. The movement may never entirely shake off their "sex cult" reputation or be taken seriously as a religion, but the members I meet don't seem to mind too much. In fact, they're all too happy and devoted to care.

@Jak_TH

Excerpt from:
UFO Religion the Ralians Know They're 'Quite Out There' - VICE UK

Read More...

Take care of your eyes by making healthy eating choices – Western Producer

January 25th, 2020 1:41 am

With the arrival of the year 2020 we are reminded that this number is often recognized as an indicator of perfect vision.

It seems appropriate in the year 2020 to consider what nutrients and foods preserve and promote vision health.

Making healthy lifestyle and diet choices can help keep our eyes healthy and may prevent age-related eye diseases, such as sight loss, dry eyes, age-related macular degeneration (AMD), cataracts, and problems with night vision.

Our eyes, like the rest of our body, benefit when we eat a balanced diet. However, there are several key nutrients that are particularly good for maintaining eye health.

Vitamin A is a fat-soluble vitamin that helps the retina to absorb light. Vitamin A deficiency is most common in developing countries. Some of the first signs of this deficiency are dry eyes and night blindness.

There are two types of vitamin A found in foods: preformed vitamin A, also known as retinol, and pro-vitamin A, known as beta carotene. Meat, fish, eggs and dairy products are common sources of vitamin A.

The body converts beta-carotene into vitamin A. A diet rich in beta-carotene helps eyes adjust to low levels of light at night. Orange-coloured fruits and vegetables like oranges, apricots, carrots, pumpkin, squash, and sweet potatoes, get their tint from the beta-carotene. High levels of this pigment are also found in parsley, spinach, kale, egg yolk, collard greens, butter, liver and cod liver oil. Some of these foods are rich in both vitamin A and beta-carotene.

To maximize the availability of the beta-carotenes, the foods should be eaten raw or lightly steamed.

Zinc is a mineral that helps release vitamin A from the liver and drive vitamin A to the retina to produce melanin, which helps protect our eyes from ultraviolet light. It can also help delay age-related sight loss and macular degeneration.

The eye itself contains high levels of zinc, particularly in the retina, and the vascular tissue surrounding the retina. Legumes like beans, peas, chickpeas and lentils add zinc to the diet. Beef is also rich in zinc; chicken breast and pork loin contain lower levels.

Vitamin C contributes to healthy blood vessels in the eye. As an antioxidant it fights against age-related eye damage and helps to absorb some of the harmful rays generated by the sun. Vitamin C is found mainly in vegetables and fresh fruits including lemons, oranges, grapefruits, strawberries and bell peppers. Kiwi is the highest fruit source of vitamin C, making it the top eye food in the fruit category. Broccoli is also a high source of vitamin C and contains lutein and zeaxanthin.

Lutein and zeaxanthin are two nutrients with antioxidant qualities that help protect against the damaging effects of UV rays. Because part of the back of the eye is made up of lutein and zeaxanthin pigment, it is essential to keep the body nourished with these minerals to maintain healthy eyes. Essentially, lutein acts like a pair of sunglasses helping to protect the retina.

Leafy green vegetables are rich in both lutein and zeaxanthin and are also a good source of vitamin C.

This combination of nutrients has the potential to reduce the progress of age-related macular degeneration and vision loss. Well-known leafy greens include spinach, kale, romaine lettuce and broccoli. Other food sources of lutein and zeaxanthin include eggs, zucchini, corn, garden peas, brussels sprouts and blueberries.

Vitamin E is another important antioxidant that protects the eyes from free-radical damage. Oxidation can cause our body to deteriorate and become prone to disease, but vitamin E protects cells in the body from this effect. It can also potentially decrease the progression of cataracts and age-related macular degeneration. Adding wheat germ to baking or as a topping on salads, oatmeal, yogurt, soups, or smoothies is an easy way to add vitamin E to the diet. Other sources of vitamin E are almonds, hazelnuts, sunflower seeds, carrots and sweet potatoes.

Omega-3 fatty acids help to protect adults from both age related macular degeneration and dry-eye syndrome. Omega-3 helps modulate the inflammation that can lead to dry eyes. Some studies have found that fish oil can reverse dry eye, including dry eye caused by too much screen time.

Oily fish are those that have oil in their gut and body tissue, and eating them offers higher levels of omega-3-rich fish oil. The fish that contains the most beneficial levels of omega-3s include tuna, salmon, trout, mackerel, sardines, anchovies and herring.

Nuts, legumes and seeds are rich in omega-3 fatty acids and also contain high levels of vitamin E. Consider incorporating walnuts, Brazil nuts, cashews, peanuts, lentils, chickpeas, ground flax seed, chia seeds and hemp seeds into your meals as garnishes or snacks.

Water is vital for eye health. Without proper hydration, your body can no longer produce tears, or keep your eyes moisturized, which may lead to eye strain or dry eye. Blurry vision, eye fatigue, and headaches are all signs that you need to drink more water.

It is recommended that healthy adults consume six to eight, eight-ounce servings of water each day. To ensure you drink enough, keep a water bottle with you and set reminders for yourself to take in more fluids, especially after physical activity.

It should be noted that diets excessively high in sugar and refined carbohydrates are a risk factor for cataracts.

Few protein sources are better than salmon when it comes to eye health. Packed with omega-3 fatty acids, salmon can help with eye inflammation and reduce the effects of vision conditions such as age-related macular degeneration, cataracts, and dry eyes syndrome.

Spinach is one of the healthiest vegetables available, full of vitamins A, B, and K, iron, and calcium, among other nutrients. The benefits of these nutrients range from acting as an anti-inflammatory and antioxidant to maintaining bone health and helping control blood pressure. Spinach also contains lutein and zeaxanthin, which are primary antioxidants in the eye that can promote eye health and help prevent eye problems such as macular degeneration.

Place the salmon in a non-stick frying pan on medium heat or use a counter top grill.

Turn after roughly four minutes on each side. The salmon should be lightly browned on the outside and slightly transparent on the inside.

While the salmon cooks, mix together the oil, vinegar, honey and Dijon mustard in a separate bowl to create the dressing.

In a large mixing bowl, pour the dressing over the spinach and add the blueberries, capers, orange or grapefruit and onions. Toss well.

Divide the salad onto two plates and top each salad with a salmon filet and a garnish of ground flax seed.

Serve immediately and enjoy!

Adapted from fyidoctors.com/assets/FYidoctors-Eats-For-Your-Eyes-Cookbook-Vol-1.pdf.

Sources: Canadian Association of Optometrists, The American Optometric Association, fyidoctors.com and healthline.com

Betty Ann Deobald is a home economist from Rosetown, Sask., and a member of Team Resources. Contact: team@producer.com.

Read the original here:
Take care of your eyes by making healthy eating choices - Western Producer

Read More...

Sight for All United Dispensing 600+ Pairs of Glasses to Kids – businessjournaldaily.com

January 25th, 2020 1:41 am

YOUNGSTOWN, Ohio The nonprofit Sight for All United is partnering with Eye Care Associates and Classic Optical Laboratories Inc. to dispense 614 pairs of glasses to children in need at Youngstown and Liberty schools this week.

While schools are required to annually screen and identify kids for vision difficulties, more than half of those identified never get an eye exam. In December 2019, Sight for All United five exam lanes in each school, providing full eye exams for children who failed vision screenings conducted by school nurses and organized by United Way of Youngstown and the Mahoning Valley.

After an eye exam, children selected frames for glasses provided by Classic Optical Laboratories. Each child will receive two pairs of glasses one for home and one for school.

Area eye doctors provided the screenings, including Drs. John Conrad, Nick Lawrence, Chris Shoemaker, Guy Barrett, Pete Sforza, Mike Woloschak, Ryan Maceyko, Brandon Maceyko, Lindsey Foster, Frank DApolito and Sergul Erzurum. All services were provided free of charge through Sight for All United and donations from DentaQuest, Essilor Vision Foundation and Classic Optical Laboratories.

Pictured: Beth Landers, Classic Optical Laboratories customer service representative, and Kim Blazek, licensed optician, assist a student with selecting frames. Image courtesy of Sight for All United.

Published by The Business Journal, Youngstown, Ohio.

CLICK HERE to subscribe to our print edition and sign up to our free daily headlines.

Read more:
Sight for All United Dispensing 600+ Pairs of Glasses to Kids - businessjournaldaily.com

Read More...

Thousands of South Africans could go blind while waiting for cataract treatment – All4Women

January 25th, 2020 1:41 am

An estimated 290 000 South Africans could become blind as a result of untreated cataracts, with government facilities in most provinces unable to meet the demand for eyesight-saving surgery and waiting-lists stretching well over a year

The Right to Sight Trust, the philanthropic arm of the Ophthalmological Society of South Africa (OSSA), has contributed over R50 million in services over the past three years to vision-restoring operations, but has now run out of funds to cover the cost of vital surgical consumables, like intraocular lens (IOL) implants that restore vision.

The Right to Sight Trust chairperson, Dr Bayanda Mbambisa, said on Thursday that, although they have been able to assist in improving access to high quality eye-care for those in need through the Second Sight Project, the organisation will struggle to accomplish its goals of ending preventable blindness in the target year of 2020.

The Right to Sight Trust and the Second Sight project, and its forerunner Eyecare 2000, are OSSAs response to the World Health Organisations (WHO) call for all countries globally to eliminate avoidable blindness by 2020.

The Second Sight Project enables cataract sufferers from low-income households who are unable to afford private medical care and have been on a public hospital waiting list for over a year to access sponsored cataract surgery.

Our initiative partners with the private and public sectors in realising the WHOs Vision 2020 ask. In the past three years, we have helped 2 071 people in South Africa. Based on a conservative estimate that one cataract sufferer impacts the lives of six people, over 12 400 individuals have benefited indirectly through this partnership that restores patients independence along with their sight, said Mbambisa.

Yet, as we enter 2020, the target year set by WHO, funds are dwindling. Its devastating that the project is once more struggling to accomplish its mission, she said.

South Africas national cataract surgery rate lags far behind international norms, even for developing countries, with the number of surgeries performed declining since the mid-2000s as government focus and funding shifted towards higher priority medical conditions.

Second Sights partnership approach includes ophthalmologists in private practice, and their anaesthetist colleagues, who donate their time and skills; private hospitals providing theatre time, and funding partners and sponsors that provide IOL lenses and consumables for cataract surgery.

Ophthalmologists who perform pro-bono surgeries are reimbursed for consumables used during the surgeries. In the annual Eye Care Awareness Week in October, medical device companies and other sponsors give ophthalmologists access to IOLs and other consumables.

Mbambisa said that in 2019, five medical device companies and three financial donors partnered on the project, with 85 ophthalmologists performing regular monthly surgeries as well as during Eye Care Awareness Week.

In 2019 alone we helped 646 people regain their sight. Whilst the bulk of the cost for the surgeries are borne by ophthalmologists and hospitals that provide free time and theatre space, there is an urgent need for funding to cover the consumables that are essential to surgery. Funding is the only obstacle that stands between this highly effective partnership model and our ability to provide sight saving surgeries.

Every donation restores the sight and dignity of one patient and filters down to a better quality of life for family members and friends who have been caring for the blind or partially sighted individual with significant positive impact on the economic and social health of families and communities. We urge those in a position to assist financially, to support us in caring for those who have no other means.

To find out how corporates can support the Second Sight Project, contact Cindy Busk, National OSSA Right to Sight Operations Manager at [emailprotected] or 082 600 5970.

Author: ANA Newswire

Read the original:
Thousands of South Africans could go blind while waiting for cataract treatment - All4Women

Read More...

Europes guardian of stem cells and hopes, real and unrealistic – Daily Times

January 23rd, 2020 11:46 pm

Poland has emerged as Europes leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industrys leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

Health insurance

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sisters stem cells into Michals bloodstream.

It was not quite enough for Michals needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, is now flourishing, both intellectually and physically, his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, each container holds up to 10,000 blood bags Safe and secure, they wait to be used in the future, its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the blood will be ready to use without the whole process of looking for a compatible donor and running blood tests, the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

Beauty products

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as sellers of hope, who make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons.

He compares them to makers of beauty products who swear their cream will rejuvenate the client by 20 years.

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

There is a list of almost 80 diseases for which stem cells could prove beneficial, US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP. But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy, he said.

Its not true, as its written sometimes, that we can already use them to fight Parkinsons disease or Alzheimers disease or diabetes.

EuroStemCell also cautions against private blood banks that advertise services to parents suggesting they should pay to freeze their childs cord blood in case its needed later in life.

Studies show it is highly unlikely that the cord blood will ever be used for their child, the network said.

It also pointed out that there could be a risk of the childs cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries however permit it while imposing strict controls.

Rapid growth

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 percent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKMs chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

Read more here:
Europes guardian of stem cells and hopes, real and unrealistic - Daily Times

Read More...

Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders – Moneycontrol.com

January 23rd, 2020 11:45 pm

The Indian Psychiatric Society (IPS) the professional body that represents psychiatrists in India, strongly condemned the use of stem cell therapy in psychiatric disorders, particularly autism, until such a time that research evidence substantiated its effectiveness.

IPS, in its position statement on stem cell therapy on January 17, said that till now, there is no scientifically validated and scrutinized research evidence that proves that stem cells are helpful in any psychiatric disorders including autism.

Autism is a complex neurodevelopmental disorder with no known single cause.

The advisory from the IPS comes at a time when stem cell therapy clinics that claim to have developed stem cell therapies to treat complex psychiatric problems such as autism, cerebral palsy (movement disorder), muscular dystrophy (weakness of muscles), mental retardation, spinal cord injury and brain stroke have mushroomed across the country.

These stem cell therapy centres extract stem cells from the bone marrow of each child and then inject it into the childs spinal canal. The whole procedure takes place under general anaesthesia.

These clinics use aggressive marketing techniques and false claims to lure parents of children who are suffering from disease like autism.

The Indian Council of Medical Research (ICMR) has already published guidelines that cover the various diseases that are applicable for stem cell treatment. No psychiatric disorders, including autism, are listed there under this advisory.

Stem cells are special human cells that have the ability to develop into many different cell types, from muscle cells to brain cells. In some cases, they also have the potential to repair damaged tissues, and provide a cure for various diseases. But the clinical evidence at this point is low.

Psychiatric disorders including autism are combined derangements of both neurodevelopmental and neurodegenerative trajectories of brain and are polygenetic in origin. So they actually are symptomatic manifestations of a variety of different pathogenetic processes about which scientific evidence is as yet inconclusive, IPS said.

Read more:
Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com

Read More...

What Will Be The Growth of Animal Stem Cell Therapy Market? Dagoretti News – Dagoretti News

January 23rd, 2020 11:45 pm

Latest release from SMI with title Animal Stem Cell Therapy Market Research Report 2019-2026 (by Product Type, End-User / Application and Regions / Countries) provides an in-depth assessment of the Animal Stem Cell Therapy including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Global Animal Stem Cell Therapy Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released BY SMI. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts, and industry-validated market data forecast until 2026.

Global Animal Stem Cell Therapy Market Segmentations

The segmentation chapter allows readers to understand aspects of the Global Animal Stem Cell Therapy Market such as products/services, available technologies, and applications. These chapters are written in a way that describes years of development and the process that will take place in the next few years. The research report also provides insightful information on new trends that are likely to define the progress of these segments over the next few years.

Download FREE Sample Report with Latest Industry Trends 2019 @ https://www.stratagemmarketinsights.com/sample/11599(**Note: Free Sample Copy Only with TOC, Graph, Charts)

Global Animal Stem Cell Therapy Market and Competitive Analysis

Know your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face a rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % market Share and Segmented Revenue of Animal Stem Cell Therapy Market

Segmentation and Targeting

Essential demographic, geographic, psychographic and behavioral information about business segments in the Animal Stem Cell Therapy market is targeted to aid in determining the features company should encompass in order to fit into the business requirements. For the Consumer-based market the study is also classified with Market Maker information in order to better understand who the clients are, their buying behavior and patterns.

*** For the global version, a list of below countries by region can be added as part of customization at minimum cost.North America (United States, Canada & Mexico)Asia-Pacific (Japan, China, India, Australia, etc)Europe (Germany, UK, France, etc)Central & South America (Brazil, Argentina, etc)Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, etc)

Animal Stem Cell Therapy Product/Service Development

Knowing how the product/services fit the needs of clients and what changes would require to make the product more attractive is the need of an hour. Useful approaches to focus group by utilizing User Testing and User Experience Research. Demand-side analysis always helps to correlate consumer preferences with innovation.

Marketing Communication and Sales Channel

Understanding marketing effectiveness on a continual basis help determine the potential of advertising and marketing communications and allow us to use best practices to utilize an untapped audience. In order to make marketers make effective strategies and identify why the target market is not giving attention, we ensure the Study is Segmented with appropriate marketing & sales channels to identify potential market size by Revenue and Volume* (if Applicable).

Pricing and Forecast

Pricing/subscription always plays an important role in buying decisions; so we have analyzed pricing to determine how customers or businesses evaluate it not just in relation to other product offerings by competitors but also with immediate substitute products. In addition to future sales Separate Chapters on Cost Analysis, Labor*, production* and Capacity are Covered.

How geography and sales fit together

This study is helpful to all operators who want to identify the exact size of their target audience at a specific geographic location. Animal Stem Cell Therapy Market allows entrepreneurs to determine local markets for business expansion. This study answers the questions below:

1. Where do the requirements come from?2. Where do non-potential customers reside?3. What is the buying behavior of customers in a specific region?4. What is the spending power of the customers in a particular region?

** Enquire for customization in Report @ https://www.stratagemmarketinsights.com/quiry/11599

Having our reviews and subscribing our report will help you solve the subsequent issues:

*Uncertainty about the future: Our research and insights help our customers predict the upcoming revenue pockets and growth areas. This will guide customers to invest their resources.

*Understanding market sentiments: It is very important to have a fair understanding of market sentiment for your strategy. Our insights will help you see every single eye on market sentiment. We maintain this analysis by working with key opinion leaders on the value chain of each industry we track.

*Understanding the most reliable investment center: Our research evaluates investment centers in the market, taking into account future demand, profits, and returns. Clients can focus on the most prestigious investment centers through market research.

*Evaluating potential business partners: Our research and insights help our clients in identifying compatible business partners.

Furthermore, the years considered for the study are as follows:

Historical year 2013-2018Base year 2018Forecast period** 2019 to 2026 [** unless otherwise stated]

More Related Reports ajitk123

See the original post here:
What Will Be The Growth of Animal Stem Cell Therapy Market? Dagoretti News - Dagoretti News

Read More...

Meet the Culprits of Cell Culture Contamination – Technology Networks

January 23rd, 2020 11:44 pm

The air is warm and humid, there is an abundance of food, and your friends come and go with their shiny toys. What sounds like a dreamy summer holiday is also the reality of in vitro cell culture experiments, and a golden opportunity for contaminants to intrude. Every person, reagent, and piece of equipment in the laboratory is a potential vehicle for invasive microbes, unwelcome cells and chemical impurities, which can create costly issues in both bench research and manufacturing. Cell culture contamination is a problem on many levels, creating immediate implications for experiments and wider issues for the scientific community.Consequences of cell culture contaminationContaminants can affect all cell characteristics (e.g. growth, metabolism, and morphology) and contribute to unreliable or erroneous experimental results. Cell culture contamination will likely create a need for experiments to be repeated, resulting in frustrating time delays and costly reagent wastage. Data derived from undetected contaminated cultures can end up published in scientific journals, allowing others to build hypotheses from dubious results. The pervasiveness of cross-contaminated and misidentified cell lines is a decades-long issue; in 1967, cell lines thought to be derived from various tissues were shown to be HeLa cells, a human cervical adenocarcinoma cell line.1 However, studies involving these misidentified cell lines continued to feature in hundreds of citations during the early 2000s.2This pattern is a well-acknowledged problem and threatens to undermine scientific integrity. The first published retraction in Nature Methods was due to cell line contamination3, and one conservative estimate of contaminated literature in 2017 found 32,755 articles reporting on research with misidentified cells.4 While many scientists may have been blissfully ignorant in the past, awareness of misidentified cell lines is growing.Deciding how best to deal with this knowledge is not straightforward and has been discussed extensively.4 In the interest of preventing further data contamination, a certificate of authentication of the origin and identity of human cells is now required by the International Journal of Cancer, and encouraged by funding agencies. Others have questioned whether mandatory testing really is the best way forward.3But what should be done about existing contaminated literature? Mass retraction of affected articles may disproportionately punish the careers of a few scientists, and could be a waste of resources containing potentially valuable data. One recently proposed system of self-retraction recommends replacing blame with praise in order to encourage self-correction.5 Post hoc labeling of published articles in the form of an expression of concern allows existing findings to remain accessible, while giving readers a chance to form their own judgement.

Lastly, pathogens carried by cells (either intentionally or accidentally) or in components of the culture medium are potential health hazards, and laboratory-acquired viral infections have been reported.6-8 Indeed, the stakes are higher when cells are to be introduced into patients, highlighting the critical importance of quality control in cell therapies.

While pipetting is a key part of everyday laboratory work, it is also one of the stages most prone to contamination. As sample contamination can affect the reliability of results, it is important to know how it can be avoided, saving both time and money. Download this poster for ten tips to avoiding contamination in pipetting.

Avoid leaving your cultures out of the incubator for extended periods

Label all cultures clearly and unambiguously

Disinfect work surfaces before and after use

Check disinfectants are effective and appropriate choices for the job

Work with only one cell culture at a time

Use separate media and reagents for each individual cell line

Quarantine new cell lines until tested negative for mycoplasma

Avoid overusing and relying on antibiotics

Record how long a cell line has been kept in cultureThe design of the laboratory can also play a role; cabinets should be placed away from through-traffic, doors and air-conditioning inlets.6 Restricting area access to allow only essential laboratory personnel to enter reduces disturbances of airflow around the microbiological safety cabinet.

Water baths, CO2 incubators, shelves and water pans are common culprits and should be cleaned or autoclaved regularly, using a chemical disinfectant where appropriate. Other routes of infection include accidental spillages, contact with non-sterile surfaces, splash-back from pipetting or pouring, microscopic aerosol, and infestation by vertebrates, dust and mites.Research groups isolating stem cells use unique cell properties to filter out undesired cells, explains Dr Mei-Ju Hsu, postdoctoral researcher in stem cell therapy at Leipzig University. Dr Hsu notes that: one of the most important features of mesenchymal stem cells is the attachment and growth on the plastic surfaces without prior coating. This step serves as a good way to eliminate the non-adherent cells (e.g. blood cells) by the removal of supernatants.

Mycoplasma is one of the most common cell culture contaminants, with six species of mycoplasma accounting for 95% of all contamination. Therefore, it is important to improve our understanding of where mycoplasma contamination can stem from and how best to prevent it. Download this infographic to discover more about mycoplasma contamination in cell culture labs.

Here is the original post:
Meet the Culprits of Cell Culture Contamination - Technology Networks

Read More...

Global Animal Stem Cell Therapy Market Trends, Size, Analysis and Forecast from 2020 to 2025 – Fusion Science Academy

January 23rd, 2020 11:44 pm

The research dives deep into the global share, size, and trends, as well as growth rate of the Animal Stem Cell Therapy market to project its progress during the forecast period, i.e., 20202025. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Animal Stem Cell Therapy market. The research segments the market on the basis of product type, application, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, demand and production capability across different countries.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Animal Stem Cell Therapy market.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.reportsweb.com/inquiry&RW00013146465/sample

Researchers conducting the research also carry out a comprehensive analysis of the recent amendments in the government regulation and their impact on the competitive landscape of the industry. The research assesses the recent progress in the competitive landscape including collaborations, joint ventures, product launches, acquisitions, and mergers, as well as investments in the sector for research and development.

The report profiles the key players in the industry along with a detailed analysis of their individual positions against the global landscape. The researcher provides an extensive analysis of the Animal Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

The major manufacturers covered in this report:

Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel, etc.

Scope of the report:

This research evaluates micro-markets and takes a closer look at the different growth trends, future prospects and regulations that will regulate the industry in the coming years. Researchers have also included a few top performers in the sector to calculate their industry shares and core competencies. The research explains technological developments in the sector along with upcoming areas of the industry that might potentially attract massive investments.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.reportsweb.com/inquiry&RW00013146465/discount

Most important Products of Animal Stem Cell Therapy covered in this report are:

Most important Application of Animal Stem Cell Therapy covered in this report are:

Scope of the study:

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsweb.com/inquiry&RW00013146465/buying

About ReportsWeb:

ReportsWeb is a one stop shop of market research reports and solutions to various companies across the world. We help our clients in their decision support system by assisting them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:

Name: Sameer JoshiEmail: [emailprotected]Phone: +1-646-491-9876

Here is the original post:
Global Animal Stem Cell Therapy Market Trends, Size, Analysis and Forecast from 2020 to 2025 - Fusion Science Academy

Read More...

Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 – Fusion Science Academy

January 23rd, 2020 11:44 pm

Global High Pressure Balloon Catheter Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global High Pressure Balloon Catheter industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2582408&source=atm

For competitor segment, the report includes global key players of High Pressure Balloon Catheter as well as some small players.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of High Pressure Balloon Catheter in these regions, from 2014 to 2025, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market includeBoston ScientificMedtronicTeleflexAbbott VascularCook MedicalOlympusBDTerumoB. BraunOptimedColoplastSIS-MedicalNordson MedicalOsypka MedicalKossel Medtech (Suzhou) Co., LtdBy the product type, the market is primarily split intoPolyurethaneNylonOthers

By the end users/application, this report covers the following segmentsHospitalsClinicsOthers

We can also provide the customized separate regional or country-level reports, for the following regions:North AmericaUnited StatesCanadaMexicoAsia-PacificChinaJapanSouth KoreaIndiaAustraliaIndonesiaThailandMalaysiaPhilippinesVietnamEuropeGermanyFranceUKItalyRussiaCentral & South AmericaBrazilMiddle East & AfricaTurkeyGCC CountriesEgyptSouth Africa

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2582408&source=atm

Important Key questions answered in High Pressure Balloon Catheter market report:

What will the market growth rate, Overview, and Analysis by Type of High Pressure Balloon Catheter in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in High Pressure Balloon Catheter market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of High Pressure Balloon Catheter market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2582408&licType=S&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe High Pressure Balloon Catheter product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of High Pressure Balloon Catheter , with price, sales, revenue and global market share of High Pressure Balloon Catheter in 2019 and 2015.

Chapter 3, the High Pressure Balloon Catheter competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the High Pressure Balloon Catheter breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, High Pressure Balloon Catheter market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe High Pressure Balloon Catheter sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to read the rest:
Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 - Fusion Science Academy

Read More...

Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 – Fusion Science Academy

January 23rd, 2020 11:44 pm

In 2019, the Stem Cell Therapy market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Stem Cell Therapy market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Stem Cell Therapy market size is projected to inflate with a CAGR of xx% during the forecast period.

In the Stem Cell Therapy market research study, 2018 is considered as the base year, and 2019-2019 is considered as the forecast period to predict the market size. Important regions emphasized in the report include region 1 (country 1, country2), region 2 (country 1, country2), and region 3 (country 1, country2).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

Global Stem Cell Therapy market report on the basis of market players

The report examines each Stem Cell Therapy market player according to its market share, production footprint, and growth rate. SWOT analysis of the players (strengths, weaknesses, opportunities and threats) has been covered in this report. Further, the Stem Cell Therapy market study depicts the recent launches, agreements, R&D projects, and business strategies of the market players including

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Report available at a discounted price exclusively!!! Offer ends today!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The Stem Cell Therapy market report answers the following queries:

The Stem Cell Therapy market report provides the below-mentioned information:

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Research Methodology of Stem Cell Therapy Market Report

The global Stem Cell Therapy market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Stem Cell Therapy market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Stem Cell Therapy market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Read more:
Soaring Demand for Clean-label Food Products to Trigger the Growth of the Stem Cell Therapy Market 2017 2025 - Fusion Science Academy

Read More...

Genome Medical Adds Population Genomics Offering to Enable Increased Access for Individuals Nationwide – P&T Community

January 23rd, 2020 11:43 pm

SOUTH SAN FRANCISCO, Jan. 23, 2020 /PRNewswire/ --Genome Medical, a leader in telegenomics-based clinical care, today announced that it has expanded its services to enable collaborative population genomics programs with health systems across the country. To support this augmented offering, the company has appointed renowned geneticist Huntington Willard, Ph.D., as Chief Scientific Officer and SVP, Medical Affairs.

Genome Medical uses its Genome Care DeliveryTM platform to drive large scale population genomics programs that will increase the understanding of genetic factors within specific populations. The information gleaned from these programs has the potential to help health systems and their clinicians understand how genetics and genomics contribute to the overall health and well-being of patients within the communities they serve.

The comprehensive range of services offered to health systems includes strategic advice and guidance; program development and implementation support; engagement of patients and providers; genetic testing coordination; and return of results to both patients and providers. Health systems will be able to create programs supported by a national network of licensed medical geneticists and genetic counselors, who are accessible on-demand through the company's telemedicine platform. This benefits not only patients and their families, but also clinicians who can receive consultation to determine appropriate clinical action plans.

"I am thrilled to bring new talent to the Genome Medical team as we expand our services," said Lisa Alderson, co-founder and CEO of Genome Medical. "Hunt has led multiple significant initiatives in genomics, including launching the National Precision Health program at Geisinger. Under his leadership, this team will help us execute on key partnerships with hospitals and health systems to further democratize genomics for all populations."

Willard brings decades of leadership experience in genetics and genomics to his position at Genome Medical, where he will oversee various strategic initiatives including clinical and research partnerships in population genomics with hospitals and health systems. He is an elected member of the National Academies of Medicine and of Sciences, a former president of the American Society of Human Genetics, and founding director of the Duke Institute for Genome Sciences and Policy. Most recently, he served as founding director of Geisinger National Precision Health.

"Genome Medical's business needs as a leading medical practice and telegenomics company align well with my expertise in developing and operating precision health initiatives," Willard said. "I look forward to working with Lisa and the team to transform the way hospitals and health systems utilize population genomics programs to improve the quality of clinical care."

In addition to Willard, Genome Medical also announced expansion of its population genomics team by welcoming two other former team members from Geisinger National, one of the world leaders in population genomics and precision health:

Genome Medical's network of genetic specialists and cloud-based Genome Care Delivery technology platform overcome the service delivery challenges in genetics. More than 50 clinicians are available for on-demand, virtual care in all 50 states across six specialty areas; this level of reach is paramount to the successful implementation of population genomics. The platform delivers education, engagement and provider-to-provider e-consultations, as well as genetic wellness assessments and screening for population health management.

About Genome MedicalGenome Medical is a national telegenomics technology, services and strategy company bringing genomic medicine to everyday care. Through our nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. We also help healthcare providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care. We are shepherding in a new era of genomic medicine by creating easy, efficient access to top genetic experts. Genome Medical is headquartered in South San Francisco. To learn more, visit http://www.genomemedical.comand follow @GenomeMed.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genome-medical-adds-population-genomics-offering-to-enable-increased-access-for-individuals-nationwide-300991681.html

SOURCE Genome Medical

Here is the original post:
Genome Medical Adds Population Genomics Offering to Enable Increased Access for Individuals Nationwide - P&T Community

Read More...

Whats wrong with my son? Wisconsin rejects $4 test for rare, terminal disease – WITI FOX 6 Milwaukee

January 23rd, 2020 11:43 pm

Please enable Javascript to watch this video

WISCONSIN RAPIDS They thought their newborn baby was perfect, but a Wisconsin couple soon discovered he had a deadly disease. The FOX6 Investigators found the state of Wisconsin has, so far, declined to test newborns for the rare condition that killed their son.

It's a genetic disorder known as Krabbe disease, which affects fewer than 1 in 100,000 children. Experts say early detection is critical to an affected child's chances of survival. Other states are adding newborn screening for Krabbe, but state officials in Wisconsin say there's not enough research to justify the four-dollar test.

The first day of parenthood is all about nerves, and relief.

"What do I do?!" Kevin Cushman recalls thinking, the day his son, Collin, was born. "'I don't know what to do!' I said, 'Is he OK?' And she said, 'He's perfect.'"

"And he was," said Judy Cushman, Collin's mom. "I mean, he was perfect when he was born. He was perfect."

Kevin always wanted a boy, but he and Judy agreed that's not what mattered most.

"Just as long as they're healthy," he said.

"As long as the child is healthy," Judy repeated. "And I had every reason to believe that my child was going to be healthy."

Ten years later, they can hardly remember thosefirst few months when Collin was just like any other baby.

What they will never forget is when everything changed.

"His whole body is stiff," Kevin says in a home video recorded when Collin was about 9 months old.

That's when Collin's muscles began to get tight. His reactions slowed. He became incessantly irritable. And, eventually, his face fell into an open-mouthed expression that would never go away.

"I remember holding Collin with tears, going, 'What's wrong with my son?'" Kevin said.

The answer was worse than they'd ever imagined. Collin had a rare, genetic disorder known as Krabbe disease. That meant he was going to die at an early age.

"You know, your dreams are shattered," Kevin said.

First, there would be years of tube feedings, vibration machines, and round-the-clock care.

"It was... challenging," Kevin said.

Collin was lucky enough to survive until the age of 9. Most Krabbe children die before they turn 2.

"It's horrifying," said Dr. Barbara Burton, a specialist in genetic medicine at Lurie Children's Hospital of Chicago.

She says Krabbe disease is a form of leukodystrophy that causes the body's nerves to degenerate.

"You lose the coating on the nerve fibers that transmit signals from one nerve cell to another," said Dr. Burton.

"So as the myelin was destroyed, [Collin] slowly lost more and more abilities," his father said.

The disease affects fewer than one in every 100,000 newborns -- perhaps even as few as one in 400,000 -- and there is no cure. There is, however, a way to treat the disease and improve a child's chance of living a longer, more functional life.

"We would've had a totally different boy," Judy said.

The trouble is, the treatment -- a hematopoietic stem cell transplant, or HSCT -- only works to treat Krabbe if it's done within a baby's first 30 days alive. Most parents have no idea their child even has the disease until symptoms surface months later.

"By the time the symptoms show themselves, it's too late," Kevin said. "There's no hope."

In 2018, Dr. Burton joined a team of experts in publishing guidelines that recommend newborns be screened for Krabbe before they leave the hospital. All 50 states already have programs to test newborns for a host of other disorders by pricking the child's heel to draw blood and placing that blood inside circles on a laboratory test card.

"It might just be another circle that they fill out," Kevin Cushman said.

New York was the first state to start testing for Krabbe in 2006, followed by Missouri, Kentucky, Ohio, Tennessee, and Illinois. At least five more states are now working to implement the screening, but so far, Wisconsin has rejected efforts to add Krabbe to the 48 disorders tested for at birth, in part, because there's not enough long-term research to prove the treatment works.

"I hear that argument over and over again, and I think it's ridiculous because the same thing could be said for almost any other condition for which we do newborn screening," said Dr. Burton.

Five years ago, the Cushmans nominated Krabbe disease for inclusion in Wisconsin's newborn screening program, but Chuck Warzecha, deputy administrator for the Wisconsin Division of Public Health, said the test results in too many "false positives."

"There are some risks and emotional impacts on the family when they get that false positive," said Warzecha.

The state's 2015 review of Krabbe testing relied on research that's now more than 10 years old and Dr. Burton says newer testing is more accurate.

"Our technology has gotten much better," said Dr. Burton.

In addition, some Krabbe patients who have gotten transplants are living longer more functional lives.

"We know if it gets detected early that it's treatable," said Senator Patrick Testin, a Stevens Point Republican. He's working on a bill to require Krabbe testing in Wisconsin -- as long as the cost doesn't derail his plan.

"Yeah, that might be a potential roadblock," Testin said.

In 2015, the state said Krabbe screening would cost an extra $300,000 a year, or roughly $4 per test.

"For $4, why wouldn't you?" Judy asked.

"Try to imagine yourself in the shoes of a family who finds out their child has Krabbe disease, and then talk about whether $4 per baby is worth it," Dr. Burton said.

"No child should have to go through this," Kevin said.

Even if Collin had been tested for Krabbe at birth, the Cushmans can't say for sure if they would have gone through with a transplant. The procedure is risky, and some children don't survive.

"I would've given anything to have had that choice," Kevin said. "Even if it didn't change the outcome. As a father, I think I would've felt at least a little more comfortable knowing that I literally did everything I could to save my child."

Of course, the risk of an early death without the transplant is 100%.

On Jan. 6, 2019 -- seven years to the day after Collin was diagnosed -- his father held him for the last time.

"I was gonna hold him as long as it took," he said. "If it took two days before he passed, I was not gonna let go of him."

It's not how the Cushmans imagined things when they welcomed their firstborn child into the world, but they couldn't have asked for a better goodbye.

"Surrounded by family," said Kevin Cushman. "It was perfect."

Krabbe is not on the federal government's recommended list of disorders for newborn screening, but two similar disorders are, including Pompe disease. The state of Wisconsin recently completed a pilot project for Pompe, and they are considering whether to test for it permanently. If they do, DHS says adding Krabbe testing after that would be less expensive than it would have been in the past, because the equipment and training would be similar.

For now, Krabbe is not part of Wisconsin's newborn screening program. The Cushmans intend to keep pushing until it is.

Krabbe is a recessive genetic disorder that is passed down, like blue eyes or attached earlobes. A child is only at risk if both parents are carriers of the mutated gene that causes Krabbe. Even then, there's only a 25% chance the child will get the Krabbe gene from both of them.

Parents can be tested before having a baby to determine if they are carriers of the disease, but -- because it is so rare -- most soon-to-be parents know nothing about it.

Even after Collin was diagnosed, the Cushmans chose to have a second child. This time, they knew there was a 25% risk the second child would have Krabbe. Judy Cushman called it "the worst lottery ever."

Fortunately for them, Kendra Cushman was born without the disease. Five years later, she is symptom free.

43.038902-87.906474

Here is the original post:
Whats wrong with my son? Wisconsin rejects $4 test for rare, terminal disease - WITI FOX 6 Milwaukee

Read More...

Autistic people have increased incidence of neurological problems – Spectrum

January 23rd, 2020 11:43 pm

Brain food: Autism appears to be closely linked to headaches.

Maya23K / iStock

People with autism have more brain-related health problems, such as headaches and epilepsy, than typical people do, according to a survey of twins1. The study is the first to look at associations between autism and physical health problems among twins.

The study found no association between autism and other physical conditions, such as gastrointestinal problems and infectious diseases, however.

I find it particularly remarkable that our results are so clear in terms of confirming that [autism] but also autistic traits are associated with neurological alterations, and no other somatic issues are equally associated, says lead investigator Sven Blte, director of the Center of Neurodevelopmental Disorders at the Karolinska Institutet in Stockholm, Sweden. The findings also support the idea that autism is a condition of the brain, Blte says, and not of the immune system or the gut.

Understanding associations such as these can help clinicians look out for autistic peoples health problems. That is particularly important when treating people who may have difficulties communicating, says Thomas Challman, medical director of the Geisinger Autism and Developmental Medicine Institute in Lewisburg, Pennsylvania.

Associated health issues can be really important in maximizing peoples quality of life, Challman says. If there is a higher rate of various other medical conditions in individuals with a developmental condition, we want to have a higher level of alertness in detecting these things.

The researchers surveyed 172 pairs of twins both identical and fraternal enrolled in the Roots of Autism and ADHD Twin Study Sweden. Of this group, 75 pairs have at least one twin with autism; 18 pairs of identical twins have only one twin with autism. Because identical twins who grow up together share a nearly identical genetic background and environment, they are particularly helpful in teasing out how these factors can shape an individuals health.

The researchers gave the participants, who ranged in age from 8 to 31 years, diagnostic exams and the Social Responsiveness Scale, Second Edition, a standard survey of autism traits. The participants or their parents then filled out a questionnaire that asked about the participants history of infectious and cardiovascular diseases, neurological problems such as epilepsy and headaches, gastrointestinal problems such as lactose intolerance, and immunological conditions such as asthma and allergies.

The researchers found that people with an autism diagnosis have more neurological and immunological health problems than those without the diagnosis. They also found that within identical twin pairs in which only one twin has autism, the twin with more neurological problems is more likely to be autistic than the neurotypical twin is.

In their analysis, the researchers weighted common problems such as headaches as equal to rarer problems such as heart defects. This approach may have affected the results, so the team should confirm the finding in a larger sample size, says Lior Brimberg, who was not involved in the research. Brimberg is assistant professor of neuroimmunology at the Feinstein Institute for Medical Research in Manhasset, New York.

The researchers also did not control for age or gender.

The fact that the study did not find an association between autism and gastrointestinal problems is surprising, notes Barbara McElhanon, assistant professor of pediatric gastroenterology at Emory University in Atlanta, Georgia, and a clinician at Childrens Healthcare of Atlanta.

The study may have missed this association because gastrointestinal problems, such as constipation, tend to be transient, she says, and may be more easily forgotten when responding to questionnaires than are persistent conditions such as epilepsy. Only 1.2 percent of the participants with autism and 0.8 percent of those without autism reported experiencing constipation both at the low end of prevalence estimates in the general public, which range from 0.7 to nearly 30 percent.

The study is also important in evaluating how much of autism and its traits are heritable versus environmental, Brimberg says.

Because identical twins share nearly all of their DNA, the association between autism and neurological problems in identical twins suggests that something beyond genetics, such as an interaction between genes and the environment, is at play in the origin of both conditions, Brimberg says.

Theyre almost sharing the same environment, theyre almost sharing the same genetics, and you still dont see 100 percent penetration of [autism], Brimberg says.

Brimberg notes that a study in July concluded that autism is 80 percent heritable2. I think this study suggests that, you know, not necessarily, she says.

The researchers hope to analyze a larger database, such as the Child and Adolescent Twin Study in Sweden, which has more than 32,000 participants. Ultimately, they say, they hope their work will help scientists identify autism subtypes and pathways that underlie the condition.

Go here to see the original:
Autistic people have increased incidence of neurological problems - Spectrum

Read More...

Myriad Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer – GlobeNewswire

January 23rd, 2020 11:43 pm

SALT LAKE CITY, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSKs PARP inhibitor Zejula (niraparib). Myriads filing is based on the positive results from the Phase 3 PRIMA trial of Zejula that was published online in the New England Journal of Medicine in September 2019.

The myChoice CDx test provides valuable molecular insights into tumors and helps identify women with ovarian cancer who are most likely to benefit from PARP inhibitors, said Nicole Lambert, president, Myriad Oncology. This regulatory submission represents another important step forward for precision medicine and ensuring that women have access to the most advanced therapies.

Myriad's myChoice CDx is the most comprehensive homologous recombination deficiency test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice CDx test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).

About Ovarian CancerOvarian cancer affects approximately 22,000 women per year in the United States according to the American Cancer Society. Typically, ovarian cancer is diagnosed at later stages when it has metastasised to other areas of the body and only 20 percent of patients are diagnosed with early stage disease. Ovarian cancer is one of the deadliest cancers with approximately 14,000 deaths per year attributed to the disease. Patients with certain characteristics such as a family history of the disease, certain genetic mutations such as those in the BRCA1 and BRCA2 genes, obesity and endometriosis face a higher risk from ovarian cancer.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

GSK is commercializing ZEJULA. ZEJULA is a registered trademark of GSK.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to women getting access to the most advanced therapies; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Excerpt from:
Myriad Submits sPMA for myChoice CDx with Zejula in First-Line Platinum Responsive Advanced Ovarian Cancer - GlobeNewswire

Read More...

St. Catherine Hospital Scientists on Pharmacogenomics and Artificial Intelligence – Total Croatia News

January 23rd, 2020 11:43 pm

January 23, 2020 - A Croatian group of scientists from the St. Catherine Special Hospital participated in the publication of yet another remarkable scientific paper, this time explaining the concept of pharmacogenomics testing based on the principles of artificial intelligence.

"Pharmacogenomics" is one of the world's leading scientific publications in the field of pharmacogenomics (PGx) and their latest issue included an article titled "Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data".

The authors are a group of the Croatian and American scientists, led by Professor Dragan Primorac, who propose the model of the systematic introduction of PGx testing into clinical practice. Along with that, they propose the implementation of the concept into the health systems of various countries, using Artificial Intelligence (AI) models, as well as some sub-systems within the AI framework, such as so-called Machine Learning.

Through the specific algorithms analysing the data, the patients' data is compared with all the data already deposited in large databases (using the Big Data approach), with the goal of optimising diagnostic procedures, the prevention of disease on time, and personalised treatment. Unlike the typical model of machine learning where the algorithms are defined by certain parameters based on expert knowledge, the concept of AI primarily uses the neural networks, continually evaluating a large amount of data and processing it in a similar manner to human thinking.

Pharmacogenomics analyses a whole series of genes, or even the entire genome, and then studies the connections between the genetic predisposition of an individual and their reaction to a drug. It helps understand why some people respond to some medicines while others don't, why some people need to have the doses of their medicines adjusted to get the perfect therapeutic response, and it can even warn you if a patient won't respond to therapy at all or even when someone will experience toxic side effects.

The model proposed in the paper is based on the experiences by the St. Catherine Hospital and the PGx testing it has been performing in cooperation with OneOme American company (a spin-off company of the famous Minnesotan Mayo Clinic).

The testing uses the RightMed system and analyses 25 genes at the same time (CYP1A2, CYP2B6, CYP2C9, CYP2C19, the CYP2C cluster, CYP2D6, CYP3A4, CYP3A5, CYP4F2, COMT, DPYD, DRD2, GRIK4, HLA-A, HLA-B, HTR2A, HTR2C, IFNL4, NUDT15, OPRM1, SLC6A4, SLCO1B1, TPMT, UGT1A1, VKORC1), which are responsible for the synthesis of the enzymes important for the drug's metabolism (especially the genes of the enzymatic system of cytochrome P450), transport proteins, receptors, other proteins important for the functioning of drugs, as well as those from the HLA system, which is important for the reactions of oversensitivity to medicines.

The system allows for the prediction of the response of each patient for over 300 of the most frequently used medicines, and so the patients are given the possibility to find the one which will help them best. All of the algorithms used in the system related to the use of the genetic information and the selection of the drug and its dosage are following the Clinical Pharmacogenetics Implementation Consortium(CPIC) guidelines.

The algorithm of the analysis of genes responsible for the drug metabolism of each patient will sort them into five categories of metabolizers: slow, intermediary, normal, fast or very fast. The paper also includes a very detailed SWOT (Strength, Weakness, Opportunity, Threat) analysis of the proposed strategy, which can lead to a significant new step in the development of modern medical sciences.

The importance of the introduction of PGx methods into routine clinical practice is best confirmed by the information recently published in the leading American medical sciences journal, JAMA, in which it was said that in the US, more than 2 million hospitalized patients have serious side-effects from the drugs they were given annually, and over 100.000 of them die. Some estimate that the number is even higher today. Today, side-effects from drugs constitute the fourth cause of mortality in all populations. In the US, the health system spends 136 billion dollars a year to mitigate the damage done by the side-effects of drugs. European data shows that between 7 and 13 percent of patients get admitted into hospitals because of the side-effects of drugs, and 30 to 50 percent of patients do not respond to therapy at all.

Professor Dragan Primorac said that the "right therapy for the right patient at the right time" is the key phrase of personalized medicine, however that can't be achieved without an insight into the molecular status of the patient.

Our goal is to reduce the morbidity caused by the side-effects of drugs to the lowest possible level, as well as to integrate pharmacogenomics through the concept of AI with all the other diagnostic procedures into an integrated system which will lead to the optimisation of diagnostic and therapeutical procedures.

The proposed concept of the integration of PGx methods into clinical practice, developed by the scientists from the St. Catherine Special Hospital and the OneOme company, has attracted huge interest on the world's health market, and the first implementation of the model outside of Croatia is soon to start in German health institutions.

More here:
St. Catherine Hospital Scientists on Pharmacogenomics and Artificial Intelligence - Total Croatia News

Read More...

Science Talk – What’s coming for cancer in the 2020s – The Institute of Cancer Research

January 23rd, 2020 11:43 pm

Image: The ICR's Dr Valeria Cazzaniga in the lab

With the turn of a new decade many people are looking at the best things that came out of the last 10 years, from films, music and gadgets to the most innovative medical advances. But amongst all the retrospection, others are choosing to look ahead.

Recently, I attended the launch of a new reportpublished by University College London(UCL) aiming to set the agenda for cancer research and care in the 2020s. The report argues that over the next few years, our ability to better control cancer will not be the result of one or two major breakthroughs, but the accumulation of incremental advances in many different areas.

One reference I loved from the report was how the worldwide pursuit of better cancer treatments is arguably the biggest scientific project in history, dwarfing even the US moon landings of the 70s, and its true I can't fit all of the really exciting things coming for cancer over the next 10 years into one blog post!

Instead, Ive picked three topics mentioned in the report that have the potential to be instrumental for better cancer control in the next decade, and what the ICR is already doing to help.

Alongside its report, UCL surveyed more than 2,000 people about their attitudes towards cancer research and treatment in 2019. Perhaps not surprisingly, given that one in two of us will be diagnosed with the disease in our lifetime, half of the British population believe that tackling cancer is their biggest public health priority.

But, will there ever be a cure for cancer? This question gets asked of our researchers often, and was addressed in a recent blog postby our CEO, Professor Paul Workman. Cancer is a disease made up of more than 200 main types, and a plethora of other molecular subtypes, so its unlikely we will ever have a single cure.

During the report launch, Professor Charles Swanton of the UCL Cancer Institute spoke of the success of the past 20 years in understanding more about the complexity, diversity and instability of cancers and how they evolve to develop drug resistance.

Cancer evolution is the cause of a vast majority of cancer deaths, and at The Institute of Cancer Research, it will be a central area of focus over the next decade.

While we share the goal of patients and the public in wanting cancer to be completely cured, focusing exclusively on curing cancer can risk overlooking some of the amazing progress that has already been made in the field with statistics showing that the average length of survival from cancer approximately doubled over a 10-year period as new targeted drugs, combination treatments and immunotherapies begin to improve long-term control.

As we begin the new decade, the ICR is launching the worlds first Darwinian drug discovery programme, within our new Centre for Cancer Drug Discovery, aimed at achieving further dramatic improvements in the proportion of patients whose disease can be controlled long term, as well as increasing the chances that patients will be cured.

We are building a new state-of-the-art drug discovery centre to develop a new generation of drugs that will make the difference to the lives of millions of people with cancer. Find out more about the Centre and about how you can help us finish it.

The Centre for Cancer Drug Discovery

At the ICR, our scientists are changing the way we think about cancer. We are combining advanced DNA sequencing and image analysis with evolutionary theory, mathematical modelling and artificial intelligence to understand and predict how cancers mutate and adapt to resist treatment.

The aim is to stay one step ahead of cancer, by creating new treatment strategies that anticipate, prevent and overcome evolution and drug resistance.

Advances in the technology to read peoples DNA have made it possible to sequence a patients whole genome or that of their tumour quickly and cheaply. That can allow researchers to predict how cancer will respond to treatment and to select the drug that is most appropriate for a patient and their tumour.

It is also increasingly possible to assess a persons risk of cancer by looking at their genetic information. These scientific advances are matched by a public appetite for genetics, which has seen enthusiastic participation in pilot studies and rather more controversially increased interest in direct-to-consumer genetic tests.

The Government have responded to increased knowledge of and interest in genetics with the imminent rollout of the NHS Genomic Medicine Service, which will embed genetic testing into primary care for the first time in the UK. The service will allow healthcare professionals to personalise treatments and interventions more than ever before.

The data gathered from this extensive testing will also be available for research once it has been anonymised so scientists can better understand cancer and its evolution. Its safe to say the Genomic Medicine Service is promising big things, and the NHS aims to embed genetic testing into routine healthcare by 2025 so watch this space!

One innovative way researchers at the ICR are using genetics to tailor cancer treatment is by looking at circulating tumour DNA DNA that has shed from tumours and circulates in the blood stream of a patient.

Circulating tumour DNA can be identified through a blood test, which is less painful than standard tissue biopsies and can often be a quicker and easier way to investigate tumour development in a patient and monitor treatment success. Results have been extremely promising.

One example is the plasmaMATCH clinical trial early results of which were released in December. In that study, ICR researchers looked at whether a blood test could detect traces of genetic faults that are known to drive breast cancer.

The study was so successful, scientists believe it is reliable enough to be routinely used by doctors in the clinic once it has passed regulatory approval.

As we learn more about cancers genetics and evolution, we start to understand the reasons for something that has been known for a long time that the more a cancer has progressed, the harder it is to treat. And that in turn is placing an increased emphasis on research to understand how cancer can be detected earlier or even prevented in the first place.

One way cancer can be detected earlier is by setting up dedicated screening programmes such as those that exist for breast cancer, bowel cancer and cervical cancer. The report from UCL called for enhanced screening programmes to improve early detection of lung cancer, but screening also has the potential to benefit many more cancer types in the future.

While screening programmes are estimated to save 10,000 lives a year in the UK through prevention and early diagnosis, there is also evidence that they are not reaching their full potential.

People live busy lives, and uptake of screening appointments is not as high as the Government would like. To address this, ministers asked Professor Sir Mike Richards, a former national cancer director, to review adult screening programmes in England.

One of the reviews key recommendations called for a new organisation to be set up that is able to manage all cancer screening under one roof. This could avoid unnecessary delays where multiple organisations are managing different aspects of the screening pathway, and might ensure accountability when things dont run smoothly.

Sir Mike also highlighted the value of targeted screening in his review. Targeted cancer screening programmes aim to identify people in the population who may have a higher risk of developing certain cancers based on factors such as genetics, lifestyle and environment. This information allows healthcare professionals to tailor screening programmes for smaller groups of people.

One example of this is with PSA testing in men which, while not proven useful in the general population, has been shown to be more effective in a smaller population of men those with a fault in their BRCA2 gene.

This research, from the IMPACT study, was conducted by researchers at the ICR. Regular screening using this test in men who have this particular gene fault could help identify those at risk of prostate cancer far sooner than current methods of diagnosis.

Targeted screening based on factors such as an individuals genetic profile will not only save the NHS money, but will avoid subjecting large numbers of people to unnecessary medical appointments.

Its an exciting time to work in the field of cancer research and treatment, and it seems pretty clear that the next 10 years are going to bring some revolutionary advances.

This blog post has highlighted just three areas where there are being dramatic advances I havent, for example, touched upon the great strides being made in areas such as precision radiotherapy, advanced imaging or AI.

Check back here in 2030, when Ill be doing a round-up of the best advances in cancer research from the last decade

Here is the original post:
Science Talk - What's coming for cancer in the 2020s - The Institute of Cancer Research

Read More...

Global CRISPR And CRISPR-Associated Genes Market Insights 2019 Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics,…

January 23rd, 2020 11:43 pm

Apex Market Research provides market research reports from more than four years. Here we have issued the research report on Global CRISPR And CRISPR-Associated Genes Market Market. The report shows the all leading market players profiles. The report represents the full market analysis of the CRISPR And CRISPR-Associated Genes market with SWOT analysis, fiscal status, present development, acquisitions, and mergers. The CRISPR And CRISPR-Associated Genes market report represents the major challenges and newer opportunities. In-depth the newer growth tactics influenced by the industry manufactures the shows the international competitive scale of this market sector. The report gives the closer views to the global vendors to understand the CRISPR And CRISPR-Associated Genes market trends and meanwhile, generate important tactical actions to boost their business. The report investigates industry growth and risk factors as well as keep updates regarding development task happening in the globe market.

Get Sample PDF for More Professional and Technical Insights at: https://www.apexmarketreports.com/Life-Science/global-crispr-and-crispr-associated-genes-market-by-451326#sample

Major Industry Player Profiles That Included by CRISPR And CRISPR-Associated Genes Market Research Report:

Thermo Fisher ScientificEditas MedicineCaribou BiosciencesCRISPR therapeuticsIntellia therapeutics, Inc.CellectisHorizon Discovery PlcSigma AldrichPrecision BiosciencesGenscriptSangamo Biosciences Inc.Lonza Group LimitedIntegrated DNA TechnologiesNew England BiolabsOrigene Technologies

Detailed view of CRISPR And CRISPR-Associated Genes Market:

For staying consistent in businesses and new initiate in the market, it is very essential to have a complete structure of the market holder. While thinking about this factor, the analysts provide a detailed view of the competitive strategies and landscape accepted by the principal players. The major feature of the market covered in this CRISPR And CRISPR-Associated Genes market report focused on opportunities, restraints, obstructions, global and regional distribution, market driving factors, and growth limiting factors.

The CRISPR And CRISPR-Associated Genes market report provides detailed data to mentor industry players while forming important business decisions. To provide this the report has used different analytical tools and procedures. In an aggressive market landscape, the report concentrate on every players detailed profile along with their product details, capacity, price, revenue, gross and contact information. CRISPR And CRISPR-Associated Genes market report consumes the production, import and export forecast by type, applications, and region with uniquely generated graph by our research team.

Market Type,

Genome EditingGenetic engineeringGRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

Market Application,

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

Customize Report And Inquiry For The CRISPR And CRISPR-Associated Genes Market Report: https://www.apexmarketreports.com/Life-Science/global-crispr-and-crispr-associated-genes-market-by-451326#inquiry

Regional Segmentation:

The report focuses on regional segmentation to assist clients to understand region-wise analysis of CRISPR And CRISPR-Associated Genes market report. The report includes the case study of the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa.

Key Objectives of This Report:

To redeem complete information to entrepreneurs about future products and technologies to be introduced in the market.To deliver access to unique information about top players of the Automotive Tyre market.The report focuses on feature about long-term and short-term strategies adopted by major players of the market along with their key developments.The report provides a country-wise analysis of the market helps to understand the market more precisely.To offer demand and growth trends of the market and segregation into segments.

Original post:
Global CRISPR And CRISPR-Associated Genes Market Insights 2019 Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics,...

Read More...

Page 712«..1020..711712713714..720730..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick